Strand Therapeutics vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic gates. STX-003 IV delivery entering clinic 2026. Phase 1 confirmed CR at ASCO 2025.
About
Strand Therapeutics is developing programmable mRNA — modified messenger RNA that incorporates synthetic gene circuits (logic gates) that restrict therapeutic protein expression to the tumor microenvironment. The company raised $153 million in Series B financing in August 2025, bringing total funding to $256 million at a ~$571 million valuation. Strand presented Phase 1 data at ASCO 2025 showing a confirmed complete response for STX-001, and its STX-003 program — which uses intravenous delivery rather than intratumoral injection — is entering clinical testing in 2026.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.